monitoring of infliximab and adalimumab has been proposed on the basis that drug levels directly relate to pharmacodynamics. If this is correct, then maintaining circulating drug levels above a therapeutic threshold concentration would be associated with better control of intestinal inflammation. There is a growing evidence base supporting this concept for infliximab, both in cross-sectional and longitudinal/ interventional studies. [14] [15] [16] [17] Drug levels above 2-3 lg/mL predict a higher chance of clinical remission 18 whereas levels over 5 lg/mL are associated with mucosal healing. 19 In contrast, published data for adalimumab are more variable; an association between low drug levels and worse outcomes has been reported by some authors, [20] [21] [22] but not by others. 23 A threshold of 4.9-5.9 lg/mL has been identified for clinical remission and >7 lg/mL for mucosal healing. 19, 24 The major reason for inter-patient variability in drug levels is differences in drug clearance and distribution in the body. Dose, schedule and route of administration account for some of the variation in pharmacokinetics between anti-TNF therapies; infliximab displays high peak concentrations with low troughs compared with a more uniform concentration-time profile with adalimumab. 25 Anti-drug antibodies and other non-immune mechanisms increase drug clearance. 26, 27 Other factors, such as weight and serum albumin have also been implicated. 28 For infliximab, the use of combination therapy with a thiopurine is superior to infliximab monotherapy for efficacy. 29 This is, in part, explained by a beneficial effect of thiopurines on infliximab pharmacokinetics by increasing drug levels and reducing immunogenicity.
The situation with adalimumab is not as clear; no difference in clinical efficacy at week 26 was observed between patients treated with adalimumab monotherapy compared to combination therapy with azathioprine amongst 176 patients with Crohn's disease in a prospective randominsed controlled trial. 30 A recent study suggested that the level of the major therapeutic metabolite of thiopurines, 6-tioguanine (TGN), required to augment infliximab levels was nearly 50% lower than that required for clinical efficacy. 31 This is important because, if replicated in subsequent studies, a lower dose of concomitant immunomodulation may be sufficient to confer optimal benefit whilst minimising toxicity.
We aimed to utilise data from a large cohort of patients with
Crohn's disease to address the following key issues in the application of therapeutic drug monitoring. First, the association of drug levels with the achievement of clinical targets from clinical to inflammatory remission for infliximab was compared with those for adalimumab and cut-off concentrations that might predict those therapeutic targets were explored. Second, patient and disease factors that might influence drug levels were investigated. Third, the association of TGN levels with infliximab and adalimumab levels was addressed in patients treated with combination therapy.
2 | ME TH ODS
| Patients and design
A cross-sectional service evaluation of therapeutic drug monitoring was performed among consecutive adult patients with Crohn's disease attending the out-patient clinics of two tertiary centres in the UK between October 2013 and April 2014. The diagnosis of Crohn's disease was based on standard criteria 32 33 an HBI ≤4 was considered remission. Systemic inflammation was assessed by serum concentrations of C-reactive protein (CRP), a value <5 mg/L being classified as remission.
Faecal calprotectin measurements were used as a surrogate marker of intestinal inflammation. Values <59 lg/g were considered normal.
Infliximab levels were performed in serum taken at trough, ie, just prior to infusions, whereas adalimumab levels were taken at any time point within a treatment cycle. Given that the majority of literature pertaining to therapeutic drug monitoring relates to samples collected at trough, we performed a sub-group analysis of adalimumab drug levels collected at trough, defined as day 13 or 14 for every-other-week, day 6 or 7 for every-week and day 9 or 10 for 10-daily dosing. In patients co-treated with azathioprine or mercaptopurine, TGN concentrations were assessed when patients had been on stable doses for at least 6 weeks. TGN concentrations >235 pmol/8x10 8 RBC were considered therapeutic. 34 In addition, the TGN cut-off value proposed by Yarur et al 31 (<125 pmol/8x10 8 RBC) was compared to 125-235 and >235 in examining the association with infliximab and adalimumab drug levels.
| Laboratory methods
Drug levels were measured on serum samples using a commercially available ELISA (Lisa-Tracker, Theradiag, Marne la Val ee, France) as per the manufacturer's instructions, which has been used in studies elsewhere. 20, 35 Samples were run in singlicate and expressed as lg/ mL. Patient samples with results above the measurement range were re-analysed on dilution with sample diluent (manual 1 in 4 dilution: 9400 final dilution factor). Free anti-infliximab or anti-adalimumab antibody were measured in parallel to drug levels using the ELISA kit. As the kit is drug-sensitive, anti-drug antibodies can only be detected in the absence of drug and were defined as detectable (≥10 ng/mL) or undetectable (<10 ng/mL). TGNs were analysed by ultra-high-performance liquid chromatography as described else- 
| Ethical considerations
As the data collected were part of routine clinical care, the study was considered a review of clinical practice and ethical approval was not required, according to the guidelines of the UK Health Research Authority. 37 All authors had access to the study data, and reviewed and approved the final manuscript. (Table S1 , published online).
ROC analysis was performed to identify optimal thresholds that best discriminated disease activity according to outcomes (Figure 2) .
A drug level above 5.7 lg/mL was associated with calprotectin normalisation (AUC=0.77, P<.0001, sensitivity=61%, specificity=88%) with a positive predictive value (PPV) of 83% and negative predictive value (NPV) of 71%. (Table 2 ). For biochemical remission, levels >3.4 lg/mL were associated with absence of systemic inflammation (AUC=0.71, P=.003, sensitivity 74%, specificity 73%, PPV 46%, NPV 90%) and, for clinical remission, >1.5 lg/mL was identified (AUC=0.67, sensitivity=86%, specificity=50%, PPV=94%, NPV=33%).
| Adalimumab drug level and disease activity
Median ( Median drug levels were no different between patients with active disease compared with those in remission, regardless of the definition employed (P>.15 for all, Figure 1 ). Sub-group analysis of drug levels stratified according to fortnightly compared to weekly dosing failed to demonstrate any difference (Table S2 , published online). Furthermore, when considering only drug levels obtained at trough or nontrough amongst all dosing regimens, there was no difference between patients in remission compared to those with active disease (Table 3) . On ROC analysis thresholds of 5.1 (AUC=0.61), 8.5 (AUC=0.49) and 7.2 (AUC=0.54) lg/mL were identified above which clinical and biochemical remission, and calprotectin normalisation were associated respectively. However, the discriminative power was poor (P>.15) ( Table 2 and Figure 3 ).
| Relationship between patient and disease factors and drug levels
Linear regression was performed to identify factors that influenced drug levels for infliximab and adalimumab. On univariate analysis (Table 4) , active mucosal inflammation was negatively associated with infliximab trough levels (P<.001). In a four-factor model, decreases in infliximab trough levels were independently predicted by elevated faecal calprotectin (b=À4.008, P<.001) and elevated CRP (b=À4.364, P=.001), and higher infliximab trough levels were predicted by infliximab dosed at 10 mg/kg/q8 (b=6.600, P<.001)
and BMI (b=0.161, P=.043) (R 2 =31%). Colonic disease was significantly associated with higher infliximab trough levels (b=2.811, P=.041), but addition of the Montreal location to the four-factor model did not improve the goodness of fit (P=.123).
Other covariates, including weight, serum albumin and combination therapy, did not influence trough levels. As anti-drug antibodies were only detected in three of 96 serum samples, they were not considered in the analysis. were inversely associated with adalimumab drug levels on univariate analysis (Table 5 ). Colonic disease, serum albumin and weekly dosing were positively associated with higher drug levels (P=.007, P=.005
and P<.001 respectively). For each additional day between last dose of adalimumab and performing drug monitoring, drug levels decreased by an average of 0.24 lg/mL (P=.002). In multivariate regression analysis increases in adalimumab drug levels were Cut-off thresholds reported in lg/mL and calculated using Youden Index. AUC, area under curve; CI, confidence interval, PPV, positive predictive value, NPV, negative predictive value.
T A B L E 3 Adalimumab drug levels in all patients with active disease, compared to remission, stratified by trough vs non-trough sampling time
Timing of drug level N
Median drug levels, HBI
P-value
Median drug levels, CRP
Median drug levels, calprotectin Drug levels reported in (lg/mL), N, number of patients; HBI, Harvey-Bradshaw Index (≤4 remission); CRP, C-reactive protein (<5 mg/L remission), calprotectin (<59 lg/g remission). However, this accounted for a relatively small amount of the variation in drug levels. Finally, no correlation was observed between TGNs and drug levels in patients treated with combination therapy with thiopurines and drug levels were similar across different TGN cut-offs.
Our findings that infliximab drug levels differ according to disease activity status were in keeping with the literature. 14,29,38,39 Earlier studies reported a threshold of 2-3 lg/mL above which clinical remission was more likely. 18 However, the endpoint of clinical remission is no longer viewed as the principle goal for treatment and a strategy targeting tighter disease control by normalisation of C-reactive protein and mucosal healing has been suggested. 40 This is an important concept as there is a poor correlation between symptoms (as reflected in disease activity indices such as the HBI) and mucosal healing, 41, 42 an endpoint associated with improved outcomes. In parallel with this new treatment paradigm, higher thresholds are reported to be needed to achieve mucosal healing. For example, a cross-sectional study in 145 patients with Crohn's disease and ulcerative colitis identified infliximab levels of 5.0 lg/mL that predicted mucosal healing and 6.8 lg/mL for CRP normalisation. 19 Similar findings have been reported by others. 24, 43 In keeping with these observations, we identified target thresholds for infliximab of 1.5, 3.4 and 5.7 lg/mL that were associated with clinical and biochemical remission and calprotectin normalisation respectively. Thus, this study with detectable levels of adalimumab, 44 there are fewer data supporting the utility of therapeutic drug monitoring with adalimumab 45 and defining a threshold above which predicts remission has proven more troublesome. For example, a post hoc analysis of data from CLASSIC I and II showed significant overlap in levels between patients with and without remission. However, another study reported adalimumab thresholds of 7.1 lg/mL that best predicted mucosal healing and 6.6 lg/mL for normalisation of CRP. 19 The key question is whether the current findings of lack of correlation of adalimumab levels with different measures of disease activity represents different pharmacokinetic-dynamic relationships for adalimumab compared with infliximab or whether it relates to other factors. First, it is unlikely that the drug-related differences were due to lack of patient numbers or methodology since the cohorts were large and patients treated with infliximab and adalimumab were examined in identical fashion. Second, since the bioavailability of adalimumab following subcutaneous administration is more variable, at least theoretically, than that for infliximab, the inter-cycle variance of levels in individual patients might be large, unduly influencing a correlative analysis. However, this was recently formally addressed and variance across cycles is very small. 46 Third, the timing of drug level measurement was not consistent in adalimumab patients whereas patients receiving infliximab always had trough levels measured. While relatively stable across fortnightly treatment cycles, adalimumab levels do start to fall from day 9 to trough, but only by a median of 20%. 46 It is not certain how such a small variance in levels would influence the results of the correlations, but sub-group analysis of the 21% of the adalimumab patients whose serum was obtained at trough failed to reveal associations between levels and outcomes. Similar analysis of samples taken at earlier points of the cycle also did not reveal associations. Fourth, it is possible that serum levels of adalimumab are poorly associated with intestinal tissue levels. This was supported by a pilot study addressing this issue by comparing serum and mucosal tissue levels of infliximab and adalimumab in Crohn's disease. 47 A significant correlation was seen in patients on infliximab (r=.51, P=.017) but not adalimumab (r=.23, P=.17). Such findings require confirmation, but perhaps provide the most logical explanation for the disparate findings from this study. Why such differences might occur between the two drugs is not understood.
T A B L E 4 Linear regression analysis of relationship between patient and disease factors and trough infliximab drug levels
Several factors were independent predictors of drug levels. As might be expected, higher doses of infliximab (10 mg/kg/q8 rather than 5 mg/kg/q6) and adalimumab (weekly vs less frequent dosing)
were associated with higher drug levels. 50 and those with rheumatoid arthritis. 51 The finding that increasing BMI is associated with higher infliximab drug levels is interesting. Higher weight will result in higher doses of infliximab being administered, but it appears that such a linear dosing plan is overcompensating for the increased clearance of infliximab, which occurs in a non-linear fashion, and the higher volume of distribution. 52 The relationship is, therefore, complex and requires further investigation. Of note, the impact of adding BMI to the model was modest, with an increase in R 2 from 28.3% to 30.8%. Low serum albumin has been associated with lower infliximab drug levels in both
Crohn's disease 52 and acute severe ulcerative colitis, 53 but to our knowledge, not with adalimumab. Ideal predictive models accounted for only 23%-31% of the variation in drug levels, which highlights the complex pharmacokinetic-dynamic interplay of monoclonal antibodies operating within biological systems.
Finally, we found no correlation between TGN concentrations and anti-TNF drug levels. We did not replicate the findings by Yarur et al. in a retrospective study of similar design, whereby TGN concentrations above a threshold of 125 pmol/8x10 8 RBC best predicted higher infliximab drug levels. However, in this study, there were few patients with levels below this threshold probably due to the use of clinical algorithms to achieve target TGN concentrations.
Nevertheless, anti-TNF drug levels in the TGN range 125-235 were similar to those >235, suggesting no pharmacokinetic advantage in dosing thiopurines to a "therapeutic" range when used in combination with infliximab or adalimumab. These results should be interpreted in the context that a difference was not identified in anti-TNF levels in patients receiving combination therapy compared to monotherapy (P=.86). Some studies have found higher drug levels in combination therapy compared with monotherapy, 54,55 whereas others have not. 22 The current findings might have related to the relatively small proportion of patients treated with monotherapy in this cohort (10% of infliximab, 20% of adalimumab) and by the likelihood that those on monotherapy who had low levels may have subsequently been escalated to combination therapy. Alternatively, this may relate to the duration of combination therapy at the time of drug level sampling, as anti-drug antibodies, which have been shown to increase drug clearance and are reduced with co-therapy with immunomodulators, occur early, generally within the first 12 months of therapy. 56 The median duration of combination therapy in the current cohort was 22 months and few had detectable anti-drug antibodies, albeit using a drug-sensitive assay. Future prospective studies randomising patients to different TGN thresholds in combination therapy compared with monotherapy are needed.
Several limitations of the study are acknowledged. First, the cross-sectional design meant samples were measured at a single point in time and patients were not followed to assess subsequent outcomes. We acknowledge that relating drug levels to outcomes at a single time point may limit the strength of the conclusions found.
Although patients were only included during maintenance therapy (>14 weeks) some patients may have been dose escalated (or dose de-escalated) prior to enrolment in the study, which may have biased the results. Second, the relationships between drug levels and disease status for infliximab identified are not necessarily causal. However, evidence from the pre-optimisation phase of the TAXIT study 57 suggests that a causal relationship between levels and disease activity does exist. Thirdly, one in five of the adalimumab samples were collected at trough, which, as outlined above, might in part explain why drug levels did not discriminate between outcomes. Fourth, we used faecal calprotectin as a surrogate of mucosal healing, rather than endoscopy, and defined normalisation as <59 lg/g. Although studies have shown good correlation between calprotectin and mucosal inflammation at endoscopy, 57 the accuracy in isolated small bowel Crohn's disease is questionable. 58 The application of such a stringent threshold is likely to select out those patients with tight disease control and hence influence the results, however, we observed good discrimination amongst infliximab treated patients but not those receiving adalimumab. Finally, we were unable to examine the impact of anti-drug antibodies given numbers were small. It is likely that this relates to our use of a drug-sensitive ELISA, whereby circulating drug binds to anti-drug antibody, or because a large proportion of patients in this cohort were treated with concomitant immunomodulation. A large body of data has consistently demonstrated that the presence of anti-drug antibodies negatively influences anti-TNF pharmacokinetics by increasing drug clearance. 59 Furthermore, although this ELISA has been used in a large number of studies exploring the utility of therapeutic drug monitoring, it is important to note that results obtained using different kits and different methodology may not correlate directly.
In conclusion, infliximab, but not adalimumab, drug levels were 
